Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Steuber

Showing results (101-110 of 209) with videos related to

Pageof 21
Sort By:
European Urology|May 24, 2008
Assessment of pathological prostate cancer characteristics in men with favorable biopsy features on predominantly sextant biopsyFelix K-H Chun, Nazareno Suardi, Umberto Capitanio, et al.
European Urology Open Science|January 17, 2025
Patient-reported Outcome Measures and Decision Regret After Prostate-specific Membrane Antigen-targeted Radioguided Surgery for Oligorecurrent Prostate CancerFabian Falkenbach, Giovanni Mazzucato, Zhe Tian, et al.
International Journal of Cancer|September 10, 2005
Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serumThomas Steuber, Andrew J Vickers, Alexander Haese, et al.
Urologic Oncology|January 24, 2025
Association between frailty and specific comorbidities on oncological outcomes in metastatic hormone-sensitive and castration resistant prostate cancerMike Wenzel, Benedikt Hoeh, Carolin Siech, et al.
World Journal of Urology|July 12, 2018
Inverse stage migration patterns in North American patients undergoing local prostate cancer treatment: a contemporary population-based update in light of the 2012 USPSTF recommendationsSami-Ramzi Leyh-Bannurah, Pierre I Karakiewicz, Raisa S Pompe, et al.
European Urology Focus|July 30, 2017
Incidence, Risk Factors, Management, and Complications of Rectal Injuries During Radical ProstatectomyPhilipp Mandel, Anna Linnemannstöns, Felix Chun, et al.
JCO Precision Oncology|December 6, 2024
Cancer-Control Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer With <i>BRCA</i> Gene or Tumor Suppressor Mutations Undergoing 177-Lutetium Prostate-Specific Membrane Antigen Radioligand TherapyMike Wenzel, Florestan Koll, Benedikt Hoeh, et al.
World Journal of Urology|February 13, 2021
Neoadjuvant treatment with androgen receptor signaling inhibitors prior to radical prostatectomy: a systematic reviewGaëtan Devos, Bram Vansevenant, Gert De Meerleer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patientsAchim Fleischmann, Thorsten Schlomm, Hartwig Huland, et al.
World Journal of Urology|March 13, 2024
Robot-assisted vs open retropubic radical prostatectomy: a propensity score-matched comparative analysis based on 15 years and 18,805 patientsFrancesca Ambrosini, Sophie Knipper, Derya Tilki, et al.
Pageof 21

Showing results (101-110 of 209) with videos related to

Sort By:
Pageof 21
European Urology|May 24, 2008
Assessment of pathological prostate cancer characteristics in men with favorable biopsy features on predominantly sextant biopsyFelix K-H Chun, Nazareno Suardi, Umberto Capitanio, et al.
European Urology Open Science|January 17, 2025
Patient-reported Outcome Measures and Decision Regret After Prostate-specific Membrane Antigen-targeted Radioguided Surgery for Oligorecurrent Prostate CancerFabian Falkenbach, Giovanni Mazzucato, Zhe Tian, et al.
International Journal of Cancer|September 10, 2005
Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serumThomas Steuber, Andrew J Vickers, Alexander Haese, et al.
Urologic Oncology|January 24, 2025
Association between frailty and specific comorbidities on oncological outcomes in metastatic hormone-sensitive and castration resistant prostate cancerMike Wenzel, Benedikt Hoeh, Carolin Siech, et al.
World Journal of Urology|July 12, 2018
Inverse stage migration patterns in North American patients undergoing local prostate cancer treatment: a contemporary population-based update in light of the 2012 USPSTF recommendationsSami-Ramzi Leyh-Bannurah, Pierre I Karakiewicz, Raisa S Pompe, et al.
European Urology Focus|July 30, 2017
Incidence, Risk Factors, Management, and Complications of Rectal Injuries During Radical ProstatectomyPhilipp Mandel, Anna Linnemannstöns, Felix Chun, et al.
JCO Precision Oncology|December 6, 2024
Cancer-Control Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer With <i>BRCA</i> Gene or Tumor Suppressor Mutations Undergoing 177-Lutetium Prostate-Specific Membrane Antigen Radioligand TherapyMike Wenzel, Florestan Koll, Benedikt Hoeh, et al.
World Journal of Urology|February 13, 2021
Neoadjuvant treatment with androgen receptor signaling inhibitors prior to radical prostatectomy: a systematic reviewGaëtan Devos, Bram Vansevenant, Gert De Meerleer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patientsAchim Fleischmann, Thorsten Schlomm, Hartwig Huland, et al.
World Journal of Urology|March 13, 2024
Robot-assisted vs open retropubic radical prostatectomy: a propensity score-matched comparative analysis based on 15 years and 18,805 patientsFrancesca Ambrosini, Sophie Knipper, Derya Tilki, et al.
Pageof 21